Assignee
SYROS PHARMACEUTICALS INC
US·25 granted patents·28 pending applications·73 citations·filing 2014–2025
Top patents by PatentIndex Score
53 records- 0194US10738067B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2020·Granted Aug 11, 2020·5 cites·30 claims
- 0293US11040957B2Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·7 cites·21 claims
- 0392US12364664B2Lyophilized compositions comprising arsenicSYROS PHARMACEUTICALS INC·Filed 2023·Granted Jul 22, 2025·1 cites·18 claims
- 0492US10336760B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Jul 2, 2019·11 cites·21 claims
- 0592US10059690B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2017·Granted Aug 28, 2018·9 cites·19 claims
- 0690US9868994B2Methods of stratifying patients for treatment with retinoic acid receptor-α agonistsSYROS PHARMACEUTICALS INC·Filed 2017·Granted Jan 16, 2018·6 cites·22 claims
- 0786US10697025B2Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2018·Granted Jun 30, 2020·3 cites·27 claims
- 0886US10308648B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Jun 4, 2019·6 cites·20 claims
- 0985US10106526B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Oct 23, 2018·5 cites·19 claims
- 1084US10519135B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2018·Granted Dec 31, 2019·3 cites·18 claims
- 1184US10240210B2Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2017·Granted Mar 26, 2019·2 cites·27 claims
- 1284US2024269076A1High Surface-Area Lyophilized Compositions Comprising Arsenic For Oral Administration In PatientsSYROS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1383US12240869B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2019·Granted Mar 4, 2025·1 cites·27 claims
- 1482US11311542B2Inhibitors of cyclin dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2019·Granted Apr 26, 2022·3 cites·20 claims
- 1581US9845508B2Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2016·Granted Dec 19, 2017·4 cites·7 claims
- 1680US11053552B2Methods of stratifying patients for treatment with retinoic acid receptor-α agonistsSYROS PHARMACEUTICALS INC·Filed 2019·Granted Jul 6, 2021·1 cites·22 claims
- 1780US10167518B2Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2017·Granted Jan 1, 2019·3 cites·7 claims
- 1879US11124527B2Compounds for the modulation of Myc activitySYROS PHARMACEUTICALS INC·Filed 2016·Granted Sep 21, 2021·2 cites·30 claims
- 1979US10865206B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2019·Granted Dec 15, 2020·1 cites·25 claims
- 2074US2023042181A1Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2173US2026035393A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2272US2021107912A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2372US2024360165A1Inhibitors of cyclin dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2471US2023144106A1Compounds for the modulation of myc activitySYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2569US2021285059A1Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2667US11447831B2Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2020·Granted Sep 20, 2022·0 cites·27 claims
- 2765US2021061803A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2865US2020010473A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2965US2019330218A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3063US11753418B2Compounds for the modulation of Myc activitySYROS PHARMACEUTICALS INC·Filed 2021·Granted Sep 12, 2023·0 cites·30 claims
- 3162US2021188833A1Compounds for the modulation of myc activitySYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3262US2022305014A1Inhibitors of cyclin dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3361US2023062491A1Inhibitors of cyclin dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3461US2024102106A1Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonistsSYROS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3560US2016264551A1Heteroaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3659US2021221820A1Compounds for the modulation of myc activitySYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3758US11083728B2Compositions of cyclin dependent kinase 7 (CDK7) inhibitorSYROS PHARMACEUTICALS INC·Filed 2018·Granted Aug 10, 2021·0 cites·15 claims
- 3857US2021147431A1Pyrrolotriazine compounds and methods of inhibiting tam kinasesSYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3956US2024091183A1Treatment regimens with fixed doses of tamibaroteneSYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4055US10787444B2Compounds for the modulation of myc activitySYROS PHARMACEUTICALS INC·Filed 2016·Granted Sep 29, 2020·0 cites·25 claims
- 4153US2016264552A1Heteromaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4252US11040981B2Pyrrolotriazine compounds and methods of inhibiting TAM kinasesSYROS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·0 cites·28 claims
- 4351US2019292167A1Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4449US2023285339A1Therapies for treating aml and uses of rara agonists, hypomethylating agents, and bcl-2 inhibitorsSYROS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4546US11918592B2Inhibitors of cyclin dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2019·Granted Mar 5, 2024·0 cites·26 claims
- 4646US11274103B2Compounds for the modulation of MYC activitySYROS PHARMACEUTICALS INC·Filed 2017·Granted Mar 15, 2022·0 cites·24 claims
- 4744US2016032387A1Methods and systems for evaluating genesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4844US2020071326A1Tam kinase inhibitorsSYROS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4941US2020291018A1Tam kinase inhibitorsSYROS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 5037US2022401489A1Compositions and methods for treating sickle cell diseaseSYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →